Citation Impact
Citing Papers
Membrane-tethered mucin-like polypeptides sterically inhibit binding and slow fusion kinetics of influenza A virus
2020 StandoutNobel
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
2011
Modulation of immune cell reactivity with cis -binding Siglec agonists
2021 StandoutNobel
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Directed evolution of cytochrome c for carbon–silicon bond formation: Bringing silicon to life
2016 StandoutScienceNobel
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
2013 StandoutScienceNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Biological Mechanism Profiling Using an Annotated Compound Library
2003
Hallmarks of Cancer: The Next Generation
2011 Standout
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
2006
The DNA-damage response in human biology and disease
2009 StandoutNature
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
2009
A view on drug resistance in cancer
2019 StandoutNature
Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors
2010
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
CD22 blockade restores homeostatic microglial phagocytosis in ageing brains
2019 StandoutNatureNobel
New treatment for acute myelogenous leukemia
2014
Increased skeletal VEGF enhances β‐catenin activity and results in excessively ossified bones
2009
Drug development from marine natural products
2008 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia
1992 Standout
Expanding the Enzyme Universe: Accessing Non‐Natural Reactions by Mechanism‐Guided Directed Evolution
2015 StandoutNobel
Use of nanoscale delivery systems to maintain synergistic drug ratiosin vivo
2010
Regulation of Ferroptotic Cancer Cell Death by GPX4
2014 Standout
Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion
2013 StandoutNobel
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
2012 Standout
Ba/F3 cells and their use in kinase drug discovery
2006
Glial and neuronal control of brain blood flow
2010 StandoutNature
Emerging drug profile: cyclin-dependent kinase inhibitors
2013
Immunotherapy and chemotherapy — a practical partnership
2005
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
2016
Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade
1997 Standout
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells
2003
Infectious and immunosuppressive complications of purine analog therapy.
1995
Classification of anticancer drugs—a new system based on therapeutic targets
2003
Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone
2014 StandoutNature
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
2013
Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks
2020 StandoutNobel
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
CASK Functions as a Mg2+-Independent Neurexin Kinase
2008 StandoutNobel
Enzymes with extra talents: moonlighting functions and catalytic promiscuity
2003
Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia
2008
Activation of Multiple Interleukin-1β Converting Enzyme Homologues in Cytosol and Nuclei of HL-60 Cells during Etoposide-induced Apoptosis
1997
DNA-PKcs has KU-dependent function in rRNA processing and haematopoiesis
2020 StandoutNatureNobel
Glycocalyx Engineering with a Recycling Glycopolymer that Increases Cell Survival In Vivo
2015 StandoutNobel
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Mevalonate pathway: A review of clinical and therapeutical implications
2007
Mitoxantrone
1996
Small RNAs are modified with N-glycans and displayed on the surface of living cells
2021 StandoutNobel
The cancer genome
2009 StandoutNature
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
The thalidomide saga
2007
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
2017 StandoutNature
Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
2012
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
1999 StandoutScience
Nanoparticle Delivery of Cancer Drugs
2011
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
2002 StandoutScience
Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials
2004
Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Mesoporous Silica Nanoparticles
2013 StandoutNobel
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Acute Myeloid Leukemia
2015 Standout
In the light of directed evolution: Pathways of adaptive protein evolution
2009 StandoutNobel
Peptidic degron for IMiD-induced degradation of heterologous proteins
2019 StandoutNobel
The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
2013
Nanoparticles in the clinic: An update
2019
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
2016
Investigational CD33-targeted therapeutics for acute myeloid leukemia
2018
Antibody therapy for acute myeloid leukaemia
2013
How I treat refractory and early relapsed acute myeloid leukemia
2015
Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia
2005
Cancer Genome Landscapes
2013 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Live-Cell Labeling of Specific Protein Glycoforms by Proximity-Enhanced Bioorthogonal Ligation
2015 StandoutNobel
Ribosomopathies: human disorders of ribosome dysfunction
2010
High-Affinity Ligand Probes of CD22 Overcome the Threshold Set by cis Ligands to Allow for Binding, Endocytosis, and Killing of B Cells
2006
P-450 Metabolites of Arachidonic Acid in the Control of Cardiovascular Function
2002
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines
2023 StandoutNobel
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
1997 StandoutScienceNobel
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
2018
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
2014
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
1993
Works of Eric J. Feldman being referenced
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
2005
A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.
1991
Apoptotic Cell Death During Treatment of Leukemias
1994
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
1993
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
2009
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195
2003
Acute Promyelocytic Leukemia: A 5-Year Experience with New Antileukemic Agents and a New Approach to Preventing Fatal Hemorrhage
1989
Farnesyltransferase inhibitors in myelodysplastic syndrome
2006
Induction of Apoptosis by Camptothecin and Topotecan
1996
Phase I Study of Bryostatin-1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma
2002
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
2006
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia
2007
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with Poor-prognosis Acute Myeloid Leukemia
2002
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
2013
Modulation of erythropoiesis by novel human bone marrow cytochrome P450- dependent metabolites of arachidonic acid
1991
High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan
2019
Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma
2004
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
2010
A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
2016
First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
2011
Abstract DDT02-04: SGN-CD33A: Preclinical and phase 1 interim clinical trial results of a CD33-directed PBD dimer antibody-drug conjugate for the treatment of acute myeloid leukemia (AML)
2015
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q
2007
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
2006
Acute myelogenous leukemia in the older patient.
1995
Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia
2005
The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death
2007
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
1990
A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
2008
Monoclonal antibody therapy in acute myeloid leukemia.
2003
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
2002
The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase
1996
Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
2014
Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias
2010
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
2007
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
2014
Phase IIb Randomized Study of CPX-351 Vs. Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: Safety Report.
2009
Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.
2006